Encapsulating Peritoneal Sclerosis in the New Millennium: A National Cohort Study

• Published in: Clinical journal of the American Society of Nephrology 2009-07, Vol.4 (7), p.1222-1229
• Main Authors: Brown, Michaela C, Simpson, Keith, Kerssens, Jan J, Mactier, Robert A
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Bacterial Infections - mortality; Cohort Studies; Epidemiology and Outcomes; Female; Humans; Incidence; Kaplan-Meier Estimate; Kidney Failure, Chronic - mortality; Kidney Failure, Chronic - therapy; Male; Middle Aged; Peritoneal Dialysis - adverse effects; Peritoneal Dialysis - mortality; Peritoneal Diseases - mortality; Peritoneal Diseases - pathology; Registries; Risk Factors; Sclerosis; Scotland - epidemiology; Young Adult
• ISSN: 1555-9041; 1555-905X
• DOI: 10.2215/CJN.01260209

The study aim was to establish the incidence and characterize all encapsulating peritoneal sclerosis (EPS) cases in patients treated by peritoneal dialysis (PD). The patient cohort, which started PD from January 1, 2000, to December 31, 2007, was identified from the Scottish Renal Registry (n = 1238). Possible EPS cases were identified by the ten adult Scottish renal units. Patient records were examined to ensure cases met diagnostic criteria. Forty-six cases were identified; 19 had their first PD exposure after January 1, 2000. The rate was 1.5%, an incidence of 4.9 per 1000 person-years. The incidence increased with PD duration, with rates of 0, 0.6, 2.0, 3.5, 8.1, 8.8 and 5% at 2 to 3, >3 to 4, >4 to 5, >5 to 6 and >6 yr PD exposure, respectively. The median PD duration of EPS cases was 5.1 yr (interquartile range [IQR] 3.4 to 6.1 yr). At diagnosis, 12 (26%) were on PD and 33 (72%) were diagnosed